This post was originally published on this site
Investing.com — Drug discovery firm Lixte Biotechnology Holdings Inc (NASDAQ:LIXT) saw its shares surge 62% on Wednesday after it revealed that its lead clinical compound, LB-100, increased the responsiveness of diverse cancers to immunotherapy in preclinical studies.
According to Lixte, LB-100, a protein phosphatase (PP2A) inhibitor, was found by researchers in Taiwan to improve the success rate of anti-cancer immunotherapy.
“Recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers,” said Lixte’s founder and CEO John Kovach.
“Unfortunately, most cancer patients do not respond to immunotherapy. There are widespread efforts to find pharmacologic and/or immunologic ways to turn unresponsive (‘cold’) tumors into responsive (‘hot’) tumors,” he added.
Lixte shares more than doubled in the early part of the Wednesday session.
